History Highlight


04 Completion of Plant
02 Pre-clinical trial product & Start pro-clinical study(Feb. 15)
Issued new shares(44million)


12 Process development for Pre-clinical trial product
Issued new shares(19million)
11 Characterization of Botulinum Toxin
10 Contracted with Pre-Clinical Trial CRO (Biotoxtech.co.Ltd)


02 Animal experimental facilities registration
01 Completed reporting of high-risk pathogen treatment research facility (No. KCDC-17-2-01)
Botulinum movement and retention report Korea Centers for Disease Control and Prevention (Management No.: 4-026-CBB-CO-040)


12 Extension of expansion of R&D Center (in Hyangnam-eup, Hwaseong-si, Gyeonggi-do)
08 Acquire license of medical device manufacturing (for export)
Acquire license of medical device manufacturing
07 Took over MEDICA Korea Co., Ltd. (USD 33million)
04 Established Seoul office (Diplomatic center)
Transferred PROTOX HQ. (Anseong GMP Factory)
03 Took over Anseong GMP factory (10,000m2) as subsidiary of DSK


12 Authorized venture company (Korea Technology Finance Corporation)
09 Established PROTOX CO., LTD.